Vanguard Group Inc 9 Meters Biopharma, Inc. Transaction History

Vanguard Group Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$0.21 - $0.32 $222,343 - $338,809	1,058,780 Added 9.2%	12,561,009 $2.7 Million
Q2 2022 Aug 12, 2022	SELL	$0.26 - $0.64 $50,931 - $125,368	-195,889 Reduced 1.67%	11,502,229 $3 Million
Q1 2022 May 13, 2022	SELL	$0.52 - $1.0 $76,110 - $146,366	-146,366 Reduced 1.24%	11,698,118 $7.01 Million
Q4 2021 Feb 14, 2022	BUY	$0.85 - $1.33 $148,593 - $232,505	174,816 Added 1.5%	11,844,484 $11.6 Million
Q3 2021 Nov 12, 2021	BUY	$1.03 - $1.41 $766,094 - $1.05 Million	743,781 Added 6.81%	11,669,668 $15.2 Million
Q2 2021 Aug 13, 2021	BUY	$1.04 - $1.5 $11.4 Million - $16.4 Million	10,925,887 New	10,925,887 $12 Million

73.4K

Ticker NMTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 12,955,400
Market Cap $259K
Description
9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders. The company is developing Larazotide, an 8-amino acid peptide, which is in Phase 3 clinical trial for the treatment of celiac disease, as we...

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

Stay updated on Vanguard Group Inc with notifications on news.